Literature DB >> 29206633

Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositis.

Cheilonda Johnson1, Paul Rosen2, Thomas Lloyd3, Maureen Horton1, Lisa Christopher-Stine4, Chester V Oddis5, Andrew L Mammen6, Sonye K Danoff7.   

Abstract

Interstitial lung disease (ILD) is common in patients with autoimmune myositis but factors that determine susceptibility are unknown. Familial and sporadic idiopathic pulmonary fibrosis (IPF) are strongly associated with a single nucleotide polymorphism in the promoter region of MUC5B (rs35705950). We sought to determine the relationship between MUC5B polymorphism expression and myositis-ILD. The MUC5B minor allele frequency (MAF) was examined in 402 European American participants; 60 with idiopathic interstitial pneumonia (IIP), 208 with myositis-ILD, and 134 unaffected controls. The MUC5B minor allele frequency was 26%, 8%, and 7% in those with non-myositis ILD, myositis-ILD, and unaffected controls, respectively. The MUC5B variant was associated with IIP (OR 4.10; p < 0.001). The MUC5B polymorphism was not significantly associated with myositis-ILD (OR 1.08; p = 0.80)]. We found MUC5B MAFs in our IIP cohort similar to published frequencies for subjects with familial and sporadic IPF. Overall, the MUC5B promoter variant does not appear to contribute to ILD risk in myositis patients.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dermatomyositis; Interstitial lung diseases; Mucin-5B; Polymyositis; Single nucleotide polymorphism

Mesh:

Substances:

Year:  2017        PMID: 29206633     DOI: 10.1016/j.rmed.2017.07.010

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  8 in total

1.  The MUC5B Promoter Polymorphism is Not Associated With Non-ILD Chronic Respiratory Diseases or Post-transplant Outcome.

Authors:  Tinne Goos; Stijn E Verleden; Laurens J De Sadeleer; Anke Van Herck; Annelore Sacreas; Arno Vanstapel; Janne Kaes; Vincent Geudens; Celine Aelbrecht; David Ruttens; Diether Lambrechts; Sascha Vermeer; Laurens J Ceulemans; Dirk E Van Raemdonck; Laurent Godinas; Jonas Yserbyt; Bart M Vanaudenaerde; Geert M Verleden; Robin Vos; Wim A Wuyts
Journal:  Transpl Int       Date:  2022-05-16       Impact factor: 3.842

2.  MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.

Authors:  Pierre-Antoine Juge; Joyce S Lee; Esther Ebstein; Hiroshi Furukawa; Evgenia Dobrinskikh; Steven Gazal; Caroline Kannengiesser; Sébastien Ottaviani; Shomi Oka; Shigeto Tohma; Naoyuki Tsuchiya; Jorge Rojas-Serrano; Montserrat I González-Pérez; Mayra Mejía; Ivette Buendía-Roldán; Ramcés Falfán-Valencia; Enrique Ambrocio-Ortiz; Effrosyni Manali; Spyros A Papiris; Theofanis Karageorgas; Dimitrios Boumpas; Katarina Antoniou; Coline H M van Moorsel; Joanne van der Vis; Yaël A de Man; Jan C Grutters; Yaping Wang; Raphaël Borie; Lidwine Wemeau-Stervinou; Benoît Wallaert; René-Marc Flipo; Hilario Nunes; Dominique Valeyre; Nathalie Saidenberg-Kermanac'h; Marie-Christophe Boissier; Sylvain Marchand-Adam; Aline Frazier; Pascal Richette; Yannick Allanore; Jean Sibilia; Claire Dromer; Christophe Richez; Thierry Schaeverbeke; Huguette Lioté; Gabriel Thabut; Nadia Nathan; Serge Amselem; Martin Soubrier; Vincent Cottin; Annick Clément; Kevin Deane; Avram D Walts; Tasha Fingerlin; Aryeh Fischer; Jay H Ryu; Eric L Matteson; Timothy B Niewold; Deborah Assayag; Andrew Gross; Paul Wolters; Marvin I Schwarz; Michael Holers; Joshua J Solomon; Tracy Doyle; Ivan O Rosas; Cornelis Blauwendraat; Mike A Nalls; Marie-Pierre Debray; Catherine Boileau; Bruno Crestani; David A Schwartz; Philippe Dieudé
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

3.  Influence of MUC5B gene on antisynthetase syndrome.

Authors:  Raquel López-Mejías; Sara Remuzgo-Martínez; Fernanda Genre; Verónica Pulito-Cueto; Sonia M Fernández Rozas; Javier Llorca; David Iturbe Fernández; Víctor M Mora Cuesta; Norberto Ortego-Centeno; Nair Pérez Gómez; Antonio Mera-Varela; Julia Martínez-Barrio; Francisco Javier López-Longo; Verónica Mijares; Leticia Lera-Gómez; María Piedad Usetti; Rosalía Laporta; Virginia Pérez; Alicia De Pablo Gafas; María Aránzazu Alfranca González; Jaime Calvo-Alén; Fredeswinda Romero-Bueno; Olga Sanchez-Pernaute; Laura Nuno; Gema Bonilla; Alejandro Balsa; Fernanda Hernández-González; Ignacio Grafia; Sergio Prieto-González; Javier Narvaez; Ernesto Trallero-Araguas; Albert Selva-O'Callaghan; Oreste Gualillo; Santos Castañeda; Lorenzo Cavagna; José M Cifrian; Miguel A González-Gay
Journal:  Sci Rep       Date:  2020-01-29       Impact factor: 4.379

Review 4.  Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).

Authors:  Paolo Spagnolo; Oliver Distler; Christopher J Ryerson; Argyris Tzouvelekis; Joyce S Lee; Francesco Bonella; Demosthenes Bouros; Anna-Maria Hoffmann-Vold; Bruno Crestani; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2020-10-09       Impact factor: 19.103

5.  Histone Deacetylase 3-Mediated Inhibition of microRNA-19a-3p Facilitates the Development of Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Authors:  Hui Yuan; Li Jiao; Nan Yu; Haifeng Duan; Yong Yu; Yanrong Bai
Journal:  Front Physiol       Date:  2020-12-04       Impact factor: 4.566

Review 6.  The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease.

Authors:  Minrui Liang; Eric L Matteson; Andy Abril; Jörg H W Distler
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-02-15       Impact factor: 5.346

Review 7.  Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response.

Authors:  Willis S Bowman; Gabrielle A Echt; Justin M Oldham
Journal:  Front Med (Lausanne)       Date:  2021-05-10

Review 8.  The Association between MUC5B Rs35705950 and Risks of Idiopathic Interstitial Pneumonia, Systemic Sclerosis Interstitial Lung Disease, and Familial Interstitial Pneumonia: A Meta-Analysis.

Authors:  Huai-Qing Lou; Chun-Xia Huang; Guang-Yi Li; Ping Li; Shou-Ming Zhang; Hai-Gang Li; Li Han; Mei-Hua Bao
Journal:  Iran J Public Health       Date:  2020-12       Impact factor: 1.429

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.